4.7 Article

Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management AKI-MATRIX

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 69, Issue 21, Pages 2592-2603

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.02.070

Keywords

bleeding; coronary intervention; creatinine; estimated glomerular filtration rate; ST-segment elevation

Funding

  1. Medicines Company
  2. Terumo
  3. Italian Society of Interventional Cardiology (GISE)
  4. St. Jude Medical
  5. Bayer Healthcare Pharmaceuticals
  6. Daiichi-Sankyo
  7. AB Medica
  8. Cardiopath
  9. AstraZeneca
  10. Abbott
  11. Cook Medical
  12. Abbott Vascular
  13. St. Jude
  14. Menarini
  15. Sanofi
  16. Boston Scientific
  17. Livanova
  18. Medtronic
  19. Eli Lilly
  20. Servier
  21. Biotronik
  22. Biosensors International
  23. Biosensors
  24. Bracco
  25. Bayer

Ask authors/readers for more resources

BACKGROUND It remains unclear whether radial access (RA), compared with femoral access (FA), mitigates the risk of acute kidney injury (AKI). OBJECTIVES The authors assessed the incidence of AKI in patients with acute coronary syndrome (ACS) enrolled in the MATRIX-Access (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox) trial. METHODS Among 8,404 patients, 194 (2.3%) were excluded due to missing creatinine values, no or an incomplete coronary angiogram, or previous dialysis. The primary AKI-MATRIX endpoint was AKI, defined as an absolute (>0.5 mg/dl) or a relative (>25%) increase in serum creatinine (sCr). RESULTS AKI occurred in 634 patients (15.4%) with RA and 712 patients (17.4%) with FA (odds ratio [OR]: 0.87; 95% confidence interval [CI]: 0.77 to 0.98; p = 0.0181). A >25% sCr increase was noted in 633 patients (15.4%) with RA and 710 patients (17.3%) with FA (OR: 0.87; 95% CI: 0.77 to 0.98; p = 0.0195), whereas a >0.5 mg/dl absolute sCr increase occurred in 175 patients (4.3%) with RA versus 223 patients (5.4%) with FA (OR: 0.77; 95% CI: 0.63 to 0.95; p = 0.0131). By implementing the Kidney Disease Improving Global Outcomes criteria, AKI was 3-fold less prevalent and trended lower with RA (OR: 0.85; 95% CI: 0.70 to 1.03; p = 0.090), with stage 3 AKI occurring in 28 patients (0.68%) with RA versus 46 patients (1.12%) with FA (p = 0.0367). Post-intervention dialysis was needed in 6 patients (0.15%) with RA and 14 patients (0.34%) with FA (p = 0.0814). Stratified analyses suggested greater benefit with RA than FA in patients at greater risk for AKI. CONCLUSIONS In ACS patients who underwent invasive management, RA was associated with a reduced risk of AKI compared with FA. (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX [MATRIX]; NCT01433627) (J Am Coll Cardiol 2017; 69: 2592-603) (C) 2017 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available